

Jawed Fareed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8839708/publications.pdf>

Version: 2024-02-01

463
papers

6,560
citations

147566

31
h-index

76769

74
g-index

466
all docs

466
docs citations

466
times ranked

10165
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
2	Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 389-396.	0.7	348
3	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1993.	3.8	221
4	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
5	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	1.8	131
6	Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1043-1057.	1.6	123
7	Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 8S-28S.	0.7	114
8	Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	82
9	Old Versus New Oral Anticoagulants: Focus on Pharmacology. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 79-99.	4.2	71
10	Protein C Antigen Deficiency and Warfarin Necrosis. <i>American Journal of Clinical Pathology</i> , 1986, 86, 653-655.	0.4	64
11	Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 1-51.	0.9	64
12	Viral Coagulopathy in Patients With COVID-19: Treatment and Care. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093677.	0.7	64
13	Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 058-073.	1.5	63
14	Generic Low-Molecular-Weight Heparins: Some Practical Considerations. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 703-713.	1.5	60
15	Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984333.	0.7	60
16	TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. <i>Thrombosis Research</i> , 1995, 77, 175-185.	0.8	59
17	Pathophysiology of Heparin-Induced Thrombocytopenia. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1657-1666.	1.2	58
18	Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. <i>Clinical Chemistry</i> , 1998, 44, 1845-1853.	1.5	57

#	ARTICLE	IF	CITATIONS
19	Zika and Chikungunya Virus and Risk for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882118.	0.7	51
20	Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments. <i>Seminars in Thrombosis and Hemostasis</i> , 1985, 11, 176-189.	1.5	50
21	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	1.2	49
22	Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile. <i>Current Pharmaceutical Design</i> , 2004, 10, 983-999.	0.9	47
23	Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2002, 105, 117-123.	0.8	44
24	Differentiation of Generic Enoxaparins Marketed in the United States by Employing NMR and Multivariate Analysis. <i>Analytical Chemistry</i> , 2015, 87, 8275-8283.	3.2	42
25	Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 267-276.	0.7	41
26	Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 520-527.	0.7	41
27	Are Inflammatory Biomarkers Increased in Varicose Vein Blood?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 656-664.	0.7	41
28	Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985216.	0.7	40
29	Thrombin Anion-binding Exosite Interactions with Heparin and Various Polyanions. <i>Annals of the New York Academy of Sciences</i> , 1989, 556, 158-165.	1.8	39
30	Attenuation of Postmeal Metabolic Indices with Red Raspberries in Individuals at Risk for Diabetes: A Randomized Controlled Trial. <i>Obesity</i> , 2019, 27, 542-550.	1.5	36
31	Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. <i>Critical Care Medicine</i> , 2020, 48, 1140-1147.	0.4	34
32	Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1925-1935.	1.9	31
33	Authentication of animal origin of heparin and low molecular weight heparin including ovine, porcine and bovine species using 1D NMR spectroscopy and chemometric tools. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 114-119.	1.4	31
34	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961990054.	0.7	30
35	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110214.	0.7	29
36	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 203-212.	3.6	28

#	ARTICLE	IF	CITATIONS
37	Global and Molecular Hemostatic Markers in Acute Myeloid Leukemia. American Journal of Clinical Pathology, 1990, 94, 397-403.	0.4	27
38	Rotational thromboelastometry (ROTEM) profiling of COVID-19 patients. Platelets, 2021, 32, 690-696.	1.1	27
39	Amidolytic Antifactor Xa Assays in the Laboratory Evaluation of Heparin and Low Molecular Weight Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 100-107.	1.5	26
40	Pharmacology of argatroban. Expert Opinion on Investigational Drugs, 1999, 8, 625-654.	1.9	26
41	Update on the safety and bioequivalence of biosimilars – focus on enoxaparin. Drug, Healthcare and Patient Safety, 2013, 5, 133.	1.0	26
42	Small-molecule direct antithrombins: argatroban. Best Practice and Research in Clinical Haematology, 2004, 17, 127-138.	0.7	25
43	Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 625-632.	0.7	25
44	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093635.	0.7	25
45	Diagnosis of Acute Megakaryoblastic Leukemia by Flow Cytometry and Immunoalkaline Phosphatase Techniques: Utilization of New Monoclonal Antibodies. American Journal of Clinical Pathology, 1988, 89, 247-253.	0.4	24
46	Differentiation of Low-Molecular-Weight Heparins: Impact on the Future of the Management of Thrombosis. Seminars in Thrombosis and Hemostasis, 2004, 30, 89-104.	1.5	24
47	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
48	Right Ventricular Outflow Doppler Predicts Low Cardiac Index in Intermediate Risk Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988606.	0.7	24
49	A Primate Model (Macaca Mulatta) to Study the Pharmacokinetics of Heparin and Its Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 138-154.	1.5	22
50	In Vitro Evaluation of Heparin Fractions: Old vs. New Methods. CRC Critical Reviews in Clinical Laboratory Sciences, 1985, 22, 361-389.	1.0	22
51	Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 718-723.	0.7	22
52	Recombinant Full-length Tissue Factor Pathway Inhibitor (TFPI) Prevents Thrombus Formation and Retrombosis after Lysis in a Rabbit Model of Jugular Vein Thrombosis. Thrombosis and Haemostasis, 1996, 76, 615-620.	1.8	22
53	Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, S63-S66.	0.7	21
54	Management of Thrombotic and Cardiovascular Disorders in the New Millenium. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 101-108.	0.7	21

#	ARTICLE	IF	CITATIONS
55	Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 542-553.	0.7	21
56	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	1.8	21
57	Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. <i>Thrombosis Research</i> , 2007, 119, 653-661.	0.8	20
58	Patients With a History of Idiopathic Deep Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and Markers of Endothelial Damage. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 124-131.	0.7	20
59	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. <i>Pharmaceuticals</i> , 2022, 15, 258.	1.7	20
60	Section Review "Cardiovascular & Renal: Recent Developments in Antithrombotic Agents. Expert Opinion on Investigational Drugs, 1995, 4, 389-412.	1.9	19
61	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 120-127.	0.7	19
62	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984752.	0.7	19
63	Oversulfated Chondroitin Sulfate Does Not Cause Augmentation in HIT Antibody Mediated Heparin-Induced Platelet Aggregation (HIPA).. <i>Blood</i> , 2009, 114, 2417-2417.	0.6	19
64	Practical Issues in the Development of Argatroban: A Perspective. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 56-65.	0.5	18
65	Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 235-240.	0.7	18
66	Angiotensin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1223-1233.	0.7	18
67	Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986349.	0.7	18
68	Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962094330.	0.7	17
69	Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its Fractions. <i>Seminars in Thrombosis and Hemostasis</i> , 1985, 11, 112-120.	1.5	16
70	Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S32-S37.	0.7	16
71	Chemometric analysis of porcine, bovine and ovine heparins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 345-352.	1.4	16
72	Porcine Mucosal Heparin Shortage Crisis! What Are the Options?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987878.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. <i>Frontiers in Medicine</i> , 2018, 5, 360.	1.2	15
74	Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093552.	0.7	15
75	Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096486.	0.7	15
76	Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. <i>FEBS Journal</i> , 1992, 203, 121-125.	0.2	14
77	Low molecular weight heparins: a developmental perspective. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 705-733.	1.9	14
78	Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 743-748.	0.7	14
79	Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 725-734.	0.7	14
80	Matrix Metalloproteinases and Their Inhibitors and Proteoglycan 4 in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961982811.	0.7	14
81	Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 385-392.	0.7	13
82	Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989512.	0.7	13
83	Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction. <i>Psychiatry Research</i> , 2020, 284, 112781.	1.7	13
84	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110566.	0.7	13
85	Antithrombin Agents: The New Class of Anticoagulant and Antithrombotic Drugs. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S45-S55.	0.7	12
86	Development of Generic Low Molecular Weight Heparins: A Perspective. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 53-68.	0.9	12
87	Inflammatory Biomarker Profiling in Total Joint Arthroplasty and Its Relevance to Circulating Levels of Lubricin, a Novel Proteoglycan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 950-959.	0.7	12
88	Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988940.	0.7	12
89	Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110131.	0.7	12
90	Synthetic Peptide Substrates in Hemostatic Testing. <i>CRC Critical Reviews in Clinical Laboratory Sciences</i> , 1983, 19, 71-134.	1.0	11

#	ARTICLE	IF	CITATIONS
91	Low Molecular Weight Heparins. <i>Drugs and Aging</i> , 1992, 2, 406-422.	1.3	11
92	Leading Article: Cardiovascular & Renal: Recombinant hirudin: A perspective. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 469-494.	1.9	11
93	Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 967-972.	0.7	11
94	Anticoagulant activity of porcine heparin: Structural-property relationship and semi-quantitative estimation by nuclear magnetic resonance (NMR) spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 639-643.	1.4	11
95	Analysis of 3-O-Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants. <i>Analytical Chemistry</i> , 2022, 94, 2950-2957.	3.2	11
96	Pharmacologic profile of certoparin. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 315-327.	1.9	10
97	Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. <i>Thrombosis Journal</i> , 2011, 9, 5.	0.9	10
98	US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 230-238.	1.0	10
99	Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 274-279.	0.7	10
100	Improving reliability of chemometric models for authentication of species origin of heparin by switching from 1D to 2D NMR experiments. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 168-174.	1.4	10
101	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19 related coagulopathy: Can defibrinolytic have a role in the early phases of coagulation disorders?" <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3111-3113.	1.9	10
102	Difficulties of Managing Submassive and Massive Pulmonary Embolism in the Era of COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1383-1387.	0.3	10
103	Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 678-686.	0.7	9
104	Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 441-446.	0.7	9
105	Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 372-376.	0.7	9
106	Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation. <i>Thrombosis Research</i> , 2017, 160, 51-57.	0.8	9
107	Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome. <i>International Angiology</i> , 2019, 38, 17-21.	0.4	9
108	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	9

#	ARTICLE	IF	CITATIONS
109	The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962095083.	0.7	9
110	An Open Label, Non-randomized, Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 66-69.	0.7	8
111	Metabolic differences of current thienopyridine antiplatelet agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 307-317.	1.5	8
112	Making headway in anticoagulant and antiplatelet therapy. <i>Nature Reviews Cardiology</i> , 2015, 12, 70-71.	6.1	8
113	Biomarker profiling of plasma samples utilizing RANDOX biochip array technology. <i>International Angiology</i> , 2017, 36, 499-504.	0.4	8
114	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1033-1041.	0.7	8
115	Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiotensin-2 and Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 269S-276S.	0.7	8
116	Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984070.	0.7	8
117	Systematic analysis of enoxaparins from different sources with online one- and two-dimensional chromatography. <i>Analyst, The</i> , 2019, 144, 3746-3755.	1.7	8
118	Comparison of outcomes in catheter-directed versus ultrasound-assisted thrombolysis for management of submassive pulmonary embolism. <i>Thrombosis Research</i> , 2021, 202, 96-99.	0.8	8
119	Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities. <i>Blood</i> , 2015, 126, 4733-4733.	0.6	8
120	Synthetic Anti-Xa Drugs Can Be Used for Parenteral Anticoagulation but Not Fondaparinux.. <i>Blood</i> , 2004, 104, 4088-4088.	0.6	8
121	Regulation of Microparticles and Adhesion Molecules in Pregnancy. Diagnostic and Pathophysiologic Implications.. <i>Blood</i> , 2007, 110, 1639-1639.	0.6	8
122	Cross Reactivity of Natural Hirudin Compared to the Recombinant Hirudins with Sheep Anti Hirudin Antibody. <i>Blood</i> , 2011, 118, 4321-4321.	0.6	8
123	Modified crush-avulsion anastomosis model on the rat femoral vein. <i>Microsurgery</i> , 1995, 16, 536-541.	0.6	7
124	Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962199556.	0.7	7
125	Compositional Differences in Commercially Available Prothrombin Complex Concentrates. <i>Blood</i> , 2012, 120, 4391-4391.	0.6	7
126	Neurological Complications of Pulmonary Embolism: a Literature Review. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 59.	2.0	7

#	ARTICLE	IF	CITATIONS
127	Emerging anticoagulant and thrombolytic drugs. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 111-135.	1.1	6
128	Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 261-267.	0.7	6
129	Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 565-572.	0.7	6
130	Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 803-807.	0.7	6
131	Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 583-588.	0.7	6
132	Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961989662.	0.7	6
133	Structural characterization of a clinically described heparin-like substance in plasma causing bleeding. <i>Carbohydrate Polymers</i> , 2020, 244, 116443.	5.1	6
134	Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989970.	0.7	6
135	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	1.5	6
136	Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs. <i>Blood</i> , 2014, 124, 4267-4267.	0.6	6
137	Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease. <i>International Journal of Angiology</i> , 2017, 26, 043-048.	0.2	5
138	Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 859-866.	0.7	5
139	Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 41-46.	0.7	5
140	Advances in Heparins and Related Research. An Epilogue. <i>Molecules</i> , 2018, 23, 390.	1.7	5
141	Vitamin D and Postoperative Vasopressor Use in Cardiopulmonary Bypass. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1322-1326.	0.7	5
142	Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants. <i>Molecules</i> , 2019, 24, 2988.	1.7	5
143	Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	5
144	Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090284.	0.7	5

#	ARTICLE	IF	CITATIONS
145	Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia.. Blood, 2010, 116, 1105-1105.	0.6	5
146	Inflammatory and Procoagulant Cytokine Levels During Pregnancy As Predictors of Adverse Complications. Blood, 2011, 118, 2296-2296.	0.6	5
147	Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thrombosis Journal, 2022, 20, 20.	0.9	5
148	Recombinant TFPI and variants:potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs, 1998, 7, 1121-1137.	1.9	4
149	Restoration of Normal Prothrombin Time/International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 85-91.	0.7	4
150	Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers. International Angiology, 2017, 36, 136-144.	0.4	4
151	Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator. Journal of Vascular Surgery, 2018, 67, 294-299.	0.6	4
152	Elevated extracellular nucleosomes and their relevance to inflammation in stage 5 chronic kidney disease. International Angiology, 2018, 37, 419-426.	0.4	4
153	The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961983806.	0.7	4
154	Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093222.	0.7	4
155	Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.. Blood, 2006, 108, 908-908.	0.6	4
156	Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia.. Blood, 2005, 106, 3970-3970.	0.6	4
157	Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions. Blood, 2008, 112, 4048-4048.	0.6	4
158	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. Blood, 2019, 134, 4945-4945.	0.6	4
159	Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110669.	0.7	4
160	The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210917.	0.7	4
161	Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 314-321.	0.7	3
162	Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 701-702.	0.7	3

#	ARTICLE	IF	CITATIONS
163	The Protective Effect of Poloxamer-188 on Platelet Functions. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 987-991.	0.7	3
164	Modulation of Interleukins in Sepsis-Associated Clotting Disorders. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 34-39.	0.7	3
165	Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial. International Angiology, 2018, 37, 427-430.	0.4	3
166	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961985643.	0.7	3
167	Time Course of Inflammatory and Procoagulant Markers in the Early Period After Total Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962098594.	0.7	3
168	Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis. Blood, 2011, 118, 1196-1196.	0.6	3
169	Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications. Blood, 2013, 122, 3641-3641.	0.6	3
170	Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays. Blood, 2016, 128, 5020-5020.	0.6	3
171	USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable,. Blood, 2021, 138, 1067-1067.	0.6	3
172	Utility of Blood Cellular Indices in the Risk Stratification of Patients Presenting with Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110522.	0.7	3
173	Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110728.	0.7	3
174	Heparan sulphate inhibition of cell proliferation induced by TGF β ² and PDGF. Mediators of Inflammation, 1993, 2, 299-302.	1.4	2
175	Apixaban to prevent venous thromboembolism after knee replacement. Lancet, The, 2010, 375, 779-780.	6.3	2
176	Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 405-411.	0.7	2
177	Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. International Angiology, 2018, 37, 255-260.	0.4	2
178	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962096082.	0.7	2
179	Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095185.	0.7	2
180	Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962096459.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors An In Vitro Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110211.	0.7	2
182	Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110149.	0.7	2
183	Novel CT-derived parameter is associated with low cardiac index in acute pulmonary embolism. <i>Thrombosis Research</i> , 2021, 202, 105-107.	0.8	2
184	Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110055.	0.7	2
185	Hemodialysis Mediated Upregulation of Myeloperoxidase in End Stage Renal Disease: Pathophysiologic Implications. <i>FASEB Journal</i> , 2007, 21, A438.	0.2	2
186	Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis. <i>Blood</i> , 2010, 116, 1401-1401.	0.6	2
187	A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Blood</i> , 2012, 120, 24-24.	0.6	2
188	Effect Of Purified Poloxamer 188 And Various Dextrans On Erythrocyte Sedimentation Rate In Healthy Subjects and Patients With Sickle Cell Disease. <i>Blood</i> , 2013, 122, 4764-4764.	0.6	2
189	Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs. <i>Blood</i> , 2013, 122, 4804-4804.	0.6	2
190	Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations.. <i>Blood</i> , 2009, 114, 4209-4209.	0.6	2
191	Effect of Dabigatran and Rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI). <i>FASEB Journal</i> , 2012, 26, 832.7.	0.2	2
192	Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110648.	0.7	2
193	Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210999.	0.7	2
194	Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211048.	0.7	2
195	Studies On The Mechanism Of Heparin Induced Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 1981, 46, 0679.	1.8	1
196	Update on the clinical applications of argatroban. <i>Future Cardiology</i> , 2006, 2, 403-414.	0.5	1
197	A Multicenter Pilot Study to Estimate the Prevalence of Bovine and Human Coagulation Antibodies in the General US Population. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 164-170.	0.7	1
198	Gender-based differences in hemostatic responses. <i>Personalized Medicine</i> , 2012, 9, 191-199.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Recombinant Factor VIIa Mediated Activation of Prothrombin Complex Concentrates. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 211-220.	0.7	1
200	National Trends for Peripheral Artery Disease and End Stage Renal Disease From the National Inpatient Sample Database. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110256.	0.7	1
201	Do we have a unified consensus on antithrombotic management of PAD?. International Angiology, 2021, 40, 229-239.	0.4	1
202	Argatroban is Capable of Passing Through the Blood Brain Barrier. Potential Implications in the Management of Thrombotic Stroke. FASEB Journal, 2007, 21, A397.	0.2	1
203	Identification of a unique plasma biomarker from patients undergoing total hip or knee replacement surgery utilizing protein chip array methods. FASEB Journal, 2008, 22, 606-606.	0.2	1
204	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962098346.	0.7	1
205	Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients. Blood, 2019, 134, 2401-2401.	0.6	1
206	Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies. Blood, 2019, 134, 2446-2446.	0.6	1
207	Sticky Platelet Syndrome: The Clinical Spectrum of Thrombosis.. Blood, 2005, 106, 4138-4138.	0.6	1
208	Factor Xa Inhibitors Can Be Differentiated in Xa, IIa and Microparticle Generation and Other Whole Blood Based Assays.. Blood, 2007, 110, 931-931.	0.6	1
209	Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.. Blood, 2009, 114, 4180-4180.	0.6	1
210	An Open Label, Non Randomized, Prospective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.. Blood, 2010, 116, 1086-1086.	0.6	1
211	Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications. Blood, 2011, 118, 2294-2294.	0.6	1
212	Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation. Blood, 2011, 118, 2302-2302.	0.6	1
213	Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins. Blood, 2012, 120, 1172-1172.	0.6	1
214	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis Associated Disseminated Intravascular Coagulation.. Blood, 2012, 120, 2223-2223.	0.6	1
215	Effect of Heparin and Its Derivatives On the Progression of Tumor Growth in Mouse Lewis Lung Carcinoma Model.. Blood, 2012, 120, 2274-2274.	0.6	1
216	Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes. Blood, 2012, 120, 3405-3405.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. Blood, 2013, 122, 1117-1117.	0.6	1
218	Neutralization Of Hemorrhage Induced By Direct Factor Xa and Thrombin Inhibitors In a Rat Model. Blood, 2013, 122, 3644-3644.	0.6	1
219	Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban. Blood, 2014, 124, 5084-5084.	0.6	1
220	Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs. Blood, 2015, 126, 4731-4731.	0.6	1
221	Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives Are Comparable in Contrast to Their Bovine Equivalents. Blood, 2016, 128, 5027-5027.	0.6	1
222	Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis Associated Coagulopathy. Blood, 2016, 128, 564-564.	0.6	1
223	Biomarker profiling of bladder cancer patients undergoing radical cystectomy: Relevance of thrombotic and inflammatory processes.. Journal of Clinical Oncology, 2012, 30, e15008-e15008.	0.8	1
224	Defibrotide Does Not Cross-React with HIT Antibodies. Implications in the Management of HIT.. Blood, 2006, 108, 1054-1054.	0.6	1
225	Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications.. Blood, 2007, 110, 3898-3898.	0.6	1
226	Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.. Blood, 2007, 110, 1992-1992.	0.6	1
227	In Vitro Characterization of the Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives.. Blood, 2007, 110, 1869-1869.	0.6	1
228	Neutralization of the Anticoagulant and Anti-Xa Effects of Fondaparinux and Idraparinux by a Novel Synthetic Antagonist. Pharmacologic Implications. FASEB Journal, 2008, 22, .	0.2	1
229	Neutralization of Hemorrhagic and Antithrombotic Activities of Heparins by a Novel Salicylamide Derivative. FASEB Journal, 2009, 23, 569.6.	0.2	1
230	Differential Modulation of Cytokines by VEGF In End Stage Renal Disease. Blood, 2010, 116, 5187-5187.	0.6	1
231	Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients. Blood, 2011, 118, 2317-2317.	0.6	1
232	Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications. Blood, 2012, 120, 3410-3410.	0.6	1
233	Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants. Blood, 2013, 122, 3642-3642.	0.6	1
234	Prevalence of Metabolic Syndrome in Patients with End Stage Renal Disease and Relevance of Biomarkers. FASEB Journal, 2015, 29, 763.4.	0.2	1

#	ARTICLE	IF	CITATIONS
235	Biomarkers of Hemostatic Dysregulation, Inflammation, and Infection in Patients Diagnosed with Sepsis Associated Coagulopathy. <i>Blood</i> , 2015, 126, 2281-2281.	0.6	1
236	Comparative Studies on the Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and Their Neutralization By FEIBA As Measured By Thromboelastography. <i>Blood</i> , 2016, 128, 2608-2608.	0.6	1
237	Biomarkers of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role. <i>Blood</i> , 2016, 128, 1412-1412.	0.6	1
238	Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux. <i>Blood</i> , 2019, 134, 1158-1158.	0.6	1
239	USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels. <i>Blood</i> , 2019, 134, 165-165.	0.6	1
240	Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects. <i>Blood</i> , 2019, 134, 3665-3665.	0.6	1
241	Impact of LMWH and Specific Factor Xa Inhibitors, Apixaban and Fondaparinux, on Cancer Cell Biology and Procoagulant Properties of Cancer Microenvironment. <i>Blood</i> , 2021, 138, 2136-2136.	0.6	1
242	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
243	Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication. <i>Blood</i> , 2020, 136, 8-8.	0.6	1
244	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022, 3, 188-203.	0.2	1
245	New Perspectives in Coagulation Testing. <i>Clinical Chemistry</i> , 1981, 27, 629-629.	1.5	0
246	Continuous Subcutaneous Heparin Infusion During Pregnancy In A Patient With A Prosthetic Mitral Valve. Clinical And Laboratory Consideration. <i>Thrombosis and Haemostasis</i> , 1981, 46, 1190.	1.8	0
247	Computed Tomography Detection Of Hemorrhagic And Thrombotic Disorders. , 1981, 46, 1435.		0
248	Effect Of Exercise On Platelet Function In Patients With Intermittent Claudication. , 1981, 46, 1405.		0
249	Antiplatelet Actions Of Low Molecular Weight Peptides And Their Derivatives. , 1981, 46, 0193.		0
250	Antithrombotic Properties Of Low Molecular Weight Heparin Fractions From Porcine Mucosal Heparin. <i>Thrombosis and Haemostasis</i> , 1981, 46, 0578.	1.8	0
251	Computerized Axial Tomographic (CAT) Diagnosis Of Vascular Thrombosis And Patency Of Aorto-Coronary Bypass Graft. <i>Thrombosis and Haemostasis</i> , 1981, 46, 0813.	1.8	0
252	The Application Of Computed Tomography In The Diagnosis And Management Of Dissecting Aortic Aneurysms. <i>Thrombosis and Haemostasis</i> , 1981, 46, 0814.	1.8	0

#	ARTICLE	IF	CITATIONS
253	Synthetic Peptide Assays For Monitoring The Defects Of Extrinsic And Intrinsic Pathways Of Coagulation: Selection Of A Suitable Substrate. , 1981, 46, 1130.		0
254	Low molecular weight heparins in pregnancy. , 0, , 341-360.		0
255	Harry L. Messmore, Jr., MD (1922â€“2011). Seminars in Thrombosis and Hemostasis, 2012, 38, 753-754.	1.5	0
256	Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 697-704.	0.7	0
257	Reversal of new oral anticoagulants and personalized medicine. Personalized Medicine, 2017, 14, 5-7.	0.8	0
258	FP327ELEVATED LEVELS OF EXTRACELLULAR NUCLEOSOMES, BIOMARKERS OF CELL DEATH, IN STAGE 5 CHRONIC KIDNEY HEMODIALYSIS (CKD5-HD) ARE INDEPENDENT OF CIRCULATING TISSUE FACTOR MICROPARTICLE COMPLEX. Nephrology Dialysis Transplantation, 2018, 33, i140-i141.	0.4	0
259	SP272PROFILING OF NEUROVASCULAR DISEASES IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE USING SPECIFIC BIOMARKER PROFILING. Nephrology Dialysis Transplantation, 2018, 33, i435-i435.	0.4	0
260	Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 314S-322S.	0.7	0
261	Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 248S-254S.	0.7	0
262	P1077PERSISTENCE OF CIRCULATING RESIDUAL HEPARIN IN ESRD PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
263	P1403PLASMA OSTEOPONTIN LEVELS DIRECTLY CORRELATE WITH INTACT PARATHYROID HORMONE AND ALKALINE PHOSPHATE LEVELS IN END STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
264	Regulation of Cortisol in Patients Undergoing Total Joint Arthroplasty. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962198761.	0.7	0
265	Biomarkers, inflammation, and thrombosis in Hepatocellular Carcinoma. FASEB Journal, 2021, 35, .	0.2	0
266	Biomarkers of Inflammation and Thrombosis in Patients Undergoing Total Joint Replacement. FASEB Journal, 2021, 35, .	0.2	0
267	Quantification of Bovine and Porcine Heparins Utilizing the Heparin Red Assay, Applications in the Study of Pharmacokinetics and Pharmacodynamics. FASEB Journal, 2021, 35, .	0.2	0
268	Comparison of Functional Methods with Absolute Quantitation of Heparin Levels in Clinical Samples as measured by Heparin Red Assay. FASEB Journal, 2021, 35, .	0.2	0
269	Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110339.	0.7	0
270	Development of Prothrombinase Induced Clotting Time (Pefakit Â®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs.. Blood, 2004, 104, 1858-1858.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Clinical Evaluation of a New Functional, Plasma-Based Assay for the Detection of Factor V Leiden - the Pefakit® APC-R Factor V Leiden Assay.. Blood, 2004, 104, 3997-3997.	0.6	0
272	Differential Digestion of Different LMWHs by Heparinase-I and Heparinase-II: Drug Developmental Implications.. Blood, 2004, 104, 4084-4084.	0.6	0
273	Discordance between the 1st and 2nd Low Molecular Weight Heparin Standards. Implications for Dosing.. Blood, 2005, 106, 4158-4158.	0.6	0
274	Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.. Blood, 2005, 106, 4116-4116.	0.6	0
275	Biochemical and Pharmacologic Profiling of a Novel Dual Acting Antithrombin Agent with Antiprotease and Antiplatelet Actions. Hematologic Implications.. Blood, 2005, 106, 1876-1876.	0.6	0
276	Relative Inhibition of Thrombin Activatable Fibrinolytic Inhibitor by Newly Developed Thrombin Inhibitors: Impact on Bleeding and Antithrombotic Actions.. Blood, 2005, 106, 4051-4051.	0.6	0
277	Differences in the native and heparinase I digestion profiles of a generic enoxaparin: Pharmacologic implications. FASEB Journal, 2006, 20, LB105.	0.2	0
278	Discordance between the 1st and 2nd low molecular weight heparin (LMWH) standards. Implications for dosing. FASEB Journal, 2006, 20, A656.	0.2	0
279	PATHOGENESIS OF ATRIAL FIBRILLATION–POTENTIAL ROLE OF INFLAMMATORY RESPONSE.. FASEB Journal, 2006, 20, A651.	0.2	0
280	Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants.. Blood, 2006, 108, 1477-1477.	0.6	0
281	Increased Levels of Inflammatory Mediators in Lung Cancer and Their Modulation by Oral Anticoagulant Treatment.. Blood, 2006, 108, 892-892.	0.6	0
282	Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications.. Blood, 2006, 108, 4016-4016.	0.6	0
283	Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm.. Blood, 2006, 108, 3838-3838.	0.6	0
284	Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.. Blood, 2006, 108, 1626-1626.	0.6	0
285	Inhibition of Heparinase I by Defibrotide: Potential Clinical Implications. FASEB Journal, 2007, 21, A1124.	0.2	0
286	Prevalence of Non–Specific Cross–Reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patient Plasma. FASEB Journal, 2007, 21, A1124.	0.2	0
287	Antiinflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors. Experimental and Clinical Observations. FASEB Journal, 2007, 21, A1127.	0.2	0
288	A Unique Biomarker Is Associated with the Prevalence of Functional Heparin Induced Thrombocytopenia (HIT) Associated Antibodies: Results from Proteomic (ProteinChip Array) Profiling of ELISA Positive HIT Plasma Samples.. Blood, 2007, 110, 3205-3205.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis.. Blood, 2007, 110, 1740-1740.	0.6	0
290	Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation.. Blood, 2007, 110, 3621-3621.	0.6	0
291	Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays.. Blood, 2007, 110, 4007-4007.	0.6	0
292	Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.. Blood, 2007, 110, 3206-3206.	0.6	0
293	Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin.. Blood, 2007, 110, 3999-3999.	0.6	0
294	Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome.. Blood, 2007, 110, 2105-2105.	0.6	0
295	Defibrotide Interactions with Anticoagulant Drugs. Developmental Implications.. FASEB Journal, 2008, 22, 1118.12.	0.2	0
296	Differential Prevalence of Anti-Heparin PF4 Immunoglobulin Subtypes in Patients Treated with Reviparin, Enoxaparin, and Certoparin. Implications in HIT Pathogenesis.. FASEB Journal, 2008, 22, 1118.13.	0.2	0
297	Pharmacokinetics of Defibrotide in Non-Human Primates is Dose Dependent.. FASEB Journal, 2008, 22, 1118.11.	0.2	0
298	Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives. FASEB Journal, 2008, 22, 1118.5.	0.2	0
299	Comparative Anticoagulant Effects of Suledoxide and Enoxaparin in Citrated Whole Blood. FASEB Journal, 2008, 22, 1118.8.	0.2	0
300	Effect of Heparin and Low Molecular Weight Heparin on the Regulation of Microparticle in Atrial Fibrillation. FASEB Journal, 2008, 22, 1118.3.	0.2	0
301	Differential Interaction of Anti-Heparin Platelet Factor 4 Antibodies with Branded and Generic Versions of Low Molecular Weight Heparins. Pathophysiologic and Bioequivalence Implications.. FASEB Journal, 2008, 22, 1118.4.	0.2	0
302	Molecular Profiling of Generic Versions of the Low Molecular Weight Heparin Enoxaparin and Their Digestion by Heparinase. FASEB Journal, 2008, 22, 1118.6.	0.2	0
303	AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis. Blood, 2008, 112, 4046-4046.	0.6	0
304	Increased Levels of Anaphylatoxin (C5a) and Bradykinin in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Potential Relevance to Heparin Mediated Hemodynamic Responses. Blood, 2008, 112, 4079-4079.	0.6	0
305	Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins. Blood, 2008, 112, 4086-4086.	0.6	0
306	Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation. Blood, 2008, 112, 5472-5472.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Fibrinokinetic Deficit in Chronic Kidney Disease and End Stage Renal Disease Patients Contributes to the Hemostatic Abnormalities. <i>Blood</i> , 2008, 112, 4078-4078.	0.6	0
308	Relative Immunologic Potential of Bovine Prothrombin and Purified Thrombins. <i>Blood</i> , 2008, 112, 5463-5463.	0.6	0
309	Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications. <i>Blood</i> , 2008, 112, 3021-3021.	0.6	0
310	A Higher Prevalence of HIT Antibodies in Patients May Be Due to Contaminated Heparin. <i>Blood</i> , 2008, 112, 3022-3022.	0.6	0
311	Selective Serotonin Reuptake Inhibitors Influence Agonist-Induced Platelet Aggregation. Preliminary Results from Comorbidity of Depression and Cardiovascular Disease Study. <i>Blood</i> , 2008, 112, 4556-4556.	0.6	0
312	Glanzmann's Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). <i>Blood</i> , 2008, 112, 1236-1236.	0.6	0
313	Bioavailability of oversulfated chondroitin sulfate in rats. Pharmacological implications in contaminated heparins. <i>FASEB Journal</i> , 2009, 23, LB401.	0.2	0
314	Biomarker profiling in elderly patients with acute hip fracture: modulation by prophylactic dosage of enoxaparin. <i>FASEB Journal</i> , 2009, 23, 569.1.	0.2	0
315	Species variation in the heparin contaminant mediated generation of kallikrein. <i>FASEB Journal</i> , 2009, 23, 569.14.	0.2	0
316	Coagulation profiling of class B vendor cats with reference to serine protease inhibitors. <i>FASEB Journal</i> , 2009, 23, 569.12.	0.2	0
317	Generic versions of argatroban can be differentiated from branded argatroban using a thrombin generation assay (TGA). <i>FASEB Journal</i> , 2009, 23, 575.1.	0.2	0
318	Does Contaminated Heparin Lead to a Higher Prevalence of HIT Antibodies?. <i>FASEB Journal</i> , 2009, 23, 569.10.	0.2	0
319	Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied using a fluorescence substrate based kinetic method. <i>FASEB Journal</i> , 2009, 23, 569.3.	0.2	0
320	Differential augmentation of the anticoagulant responses by newly developed oral anti-Xa and anti-IIa drugs in patients with liver disease. <i>FASEB Journal</i> , 2009, 23, LB383.	0.2	0
321	Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin?. <i>Blood</i> , 2009, 114, 4182-4182.	0.6	0
322	Gender-Based Differences in Hemostatic Responses. Implications in Effective Anticoagulant Management.. <i>Blood</i> , 2009, 114, 2103-2103.	0.6	0
323	Persistent Inhibition of Thrombin Generation After Intravenous Administration of Enoxaparin in Primates.. <i>Blood</i> , 2009, 114, 2095-2095.	0.6	0
324	Pharmacodynamic Differences of An Anti-Xa Enriched Low Molecular Weight Heparin, AVE 5026 in Comparison to Enoxaparin and Unfractionated Heparin.. <i>Blood</i> , 2009, 114, 4171-4171.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs with Human $\hat{\pm}$ -Thrombin and a Recombinant Version of Human Thrombin (Recothrom $\hat{\alpha},\hat{\phi}$).. Blood, 2009, 114, 4211-4211.	0.6	0
326	Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation.. Blood, 2009, 114, 2094-2094.	0.6	0
327	Thrombin Generation Assessment in Platelet Rich Plasma Offers Additional Criteria for Low Molecular Weight Heparin Antithrombotic Fingerprint Characterization.. Blood, 2009, 114, 4177-4177.	0.6	0
328	Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin.. Blood, 2009, 114, 3133-3133.	0.6	0
329	Comparative Studies On Heparin Contaminant Interactions with Normals, Liver Disease, Heparin Treated and Oral Anticoagulant Treated Patients Plasma.. Blood, 2009, 114, 2093-2093.	0.6	0
330	Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations.. Blood, 2009, 114, 1070-1070.	0.6	0
331	Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications.. Blood, 2009, 114, 3128-3128.	0.6	0
332	Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications.. Blood, 2009, 114, 1069-1069.	0.6	0
333	Cross $\hat{\alpha}$ Reactivity of Rabbit Anti $\hat{\alpha}$ Bovine Thrombin IgGs with a Human Plasma Derived Thrombin Preparation (Evithrom $\hat{\alpha},\hat{\phi}$). FASEB Journal, 2010, 24, 951.11.	0.2	0
334	Potency Adjustment of Unfractionated Heparins to Harmonize the USP and WHO Standardization. Impact on Anticoagulant Practice in the US. FASEB Journal, 2010, 24, 951.8.	0.2	0
335	Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation. FASEB Journal, 2010, 24, 951.4.	0.2	0
336	Comparative Studies on Branded Dalteparin with Two Generic Versions: Hepagumin and Fluzepamin. FASEB Journal, 2010, 24, 951.7.	0.2	0
337	Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease. FASEB Journal, 2010, 24, 1030.4.	0.2	0
338	Baseline and Serial Microparticle Concentration Analysis in Elderly Patients with Acute Hip Fracture Treated with Heparins. FASEB Journal, 2010, 24, 1b430.	0.2	0
339	Elevated Levels of Circulating Microparticles in Disseminated Intravascular Coagulation and Their Impact on the Inflammatory Process. FASEB Journal, 2010, 24, 951.13.	0.2	0
340	Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations. Blood, 2010, 116, 5131-5131.	0.6	0
341	Dysregulation of Inflammatory and Hemostatic Markers In Disseminated Intravascular Coagulation.. Blood, 2010, 116, 3656-3656.	0.6	0
342	Measurements of Prothrombin Fragment 1.2 In Urine and Blood to Assess Hypercoagulability In Preeclampsia. Blood, 2010, 116, 3174-3174.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Upregulation of Inflammatory Mediators In End-Stage Renal Disease as Measured Via Biochip Array Technology. <i>Blood</i> , 2010, 116, 5186-5186.	0.6	0
344	Differential Prevalence of Anti-Heparin-Platelet Factor 4 Antibodies In Elderly Patients with Acute Hip Fracture Undergoing Orthopaedic Surgery and Anticoagulated with Unfractionated Heparin and Enoxaparin. <i>Blood</i> , 2010, 116, 4217-4217.	0.6	0
345	Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin. <i>Blood</i> , 2010, 116, 4394-4394.	0.6	0
346	Biochip Array Profiling of Inflammatory Cytokines and Growth Factors In End-Stage Renal Disease: Hematological Implications?. <i>Blood</i> , 2010, 116, 5184-5184.	0.6	0
347	Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox). <i>Blood</i> , 2010, 116, 4385-4385.	0.6	0
348	Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects.. <i>Blood</i> , 2010, 116, 1091-1091.	0.6	0
349	Upregulation of Von Willebrand Factor, Von Wilebrand Factor Propeptide, and ADMATS-13 In End-Stage Renal Disease. <i>Blood</i> , 2010, 116, 5189-5189.	0.6	0
350	Cross Reactivity of Rabbit Anti-Recothrom (Human Recombinant Thrombin) Antibodies with Molecular Variants of Human Thrombin, and Various Bovine Thrombin Preparations. <i>Blood</i> , 2010, 116, 4418-4418.	0.6	0
351	Activation Markers of Thrombogenesis and Endothelial Dysfunction In End-Stage Renal Disease. <i>Blood</i> , 2010, 116, 5183-5183.	0.6	0
352	Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody. <i>Blood</i> , 2010, 116, 4386-4386.	0.6	0
353	Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays. <i>Blood</i> , 2010, 116, 5129-5129.	0.6	0
354	Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.. <i>Blood</i> , 2010, 116, 1098-1098.	0.6	0
355	Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs. <i>Blood</i> , 2010, 116, 3334-3334.	0.6	0
356	Protein Chip Array Profiling of Molecular Variants of Hirudins Using Surface Enhanced Laser Desorption Ionization (SELDI) Technique. <i>FASEB Journal</i> , 2011, 25, 1002.18.	0.2	0
357	Increased prevalence of Anti-Heparin Platelet factor 4 antibodies in patients with sepsis associated Disseminated Intravascular Coagulation. <i>FASEB Journal</i> , 2011, 25, 1002.1.	0.2	0
358	Identification of Unique Biomarkers in Sepsis Associated Coagulopathy. <i>Blood</i> , 2011, 118, 1237-1237.	0.6	0
359	Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin. <i>Blood</i> , 2011, 118, 1251-1251.	0.6	0
360	Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma. <i>Blood</i> , 2011, 118, 4328-4328.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,. Blood, 2011, 118, 3363-3363.	0.6	0
362	Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides. Blood, 2011, 118, 2231-2231.	0.6	0
363	Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications. Blood, 2011, 118, 1249-1249.	0.6	0
364	Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy,. Blood, 2011, 118, 3341-3341.	0.6	0
365	Comparison of the Pharmacokinetic and Pharmacodynamic Behavior of Branded and Generic Enoxaparin in Non-Human Primates. Blood, 2011, 118, 1254-1254.	0.6	0
366	Thrombotic and Inflammatory Mediators in Cancer Patients Are Downregulated by Enoxaparin. Biochip and Protein Array Analysis. Blood, 2011, 118, 713-713.	0.6	0
367	Markers of Thrombogenesis Activation and Endothelial Dysfunction in End Stage Renal Disease. Blood, 2011, 118, 1151-1151.	0.6	0
368	Generic Low Molecular Weight Heparins May Not Have the Same Safety & Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome. Blood, 2011, 118, 2308-2308.	0.6	0
369	Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants. Blood, 2011, 118, 4326-4326.	0.6	0
370	Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants. Blood, 2011, 118, 4322-4322.	0.6	0
371	Biological Activities of Two Ultra-Low Molecular Weight Heparins, Semuloparin and Bemiparin, Reveal That a Common Potency Standard Is Inadequate. Blood, 2011, 118, 4324-4324.	0.6	0
372	Non–antithrombin affinity Semuloparin and it's component oligosaccharides release endogenous TFPI in a molecular weight dependent fashion. FASEB Journal, 2012, 26, 832.5.	0.2	0
373	Tissue factor mediated generation of thrombin in prothrombin complexes is inhibited by anti–Xa based parenteral and oral agents but not by parenteral and oral antithrombin agents. Results from proteomic profiling using protein chip arrays. FASEB Journal, 2012, 26, lb537.	0.2	0
374	Evaluation of the Antithrombotic and Hemorrhagic Effects of a Novel Ultra Low Molecular Weight Heparin (ULMWH). FASEB Journal, 2012, 26, 832.3.	0.2	0
375	Comparative studies on the effect of newer oral anticoagulants on platelet aggregation. Pharmacological and developmental implications. FASEB Journal, 2012, 26, lb497.	0.2	0
376	Further Studies on the Isolation and Characterization of Heparin Contaminants Isolated From Recalled Batches of Unfractionated Heparin. FASEB Journal, 2012, 26, 1115.18.	0.2	0
377	Despite Pharmaceutical Equivalence, Generic Versions of Enoxaparin May Differ in Their Pharmacodynamic Actions. Potential Clinical Implications. FASEB Journal, 2012, 26, 832.6.	0.2	0
378	The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin.. Journal of Clinical Oncology, 2012, 30, e13117-e13117.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Effect of heparin and its derivatives on the progression of tumor growth in mouse Lewis lung carcinoma model.. Journal of Clinical Oncology, 2012, 30, e13115-e13115.	0.8	0
380	Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in End Stage Renal Disease Patients. Blood, 2012, 120, 3412-3412.	0.6	0
381	Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin.. Blood, 2012, 120, 2264-2264.	0.6	0
382	Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs. Blood, 2012, 120, 3421-3421.	0.6	0
383	Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents. Blood, 2012, 120, 3411-3411.	0.6	0
384	Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin. Blood, 2012, 120, 1131-1131.	0.6	0
385	Biochemical and pharmacological differentiation of dabigatran, apixaban and rivaroxaban. FASEB Journal, 2013, 27, lb504.	0.2	0
386	Comparative hemmorrhagic studies on dabigatran, apixaban and rivaroxaban in a rat tail bleeding model. FASEB Journal, 2013, 27, lb505.	0.2	0
387	Compositional differences in commercial available prothrombin complex concentrates and their activation by tissue factor. FASEB Journal, 2013, 27, 871.1.	0.2	0
388	A Comparison Of Hemostatic and Inflammatory Markers In Overt and Non-Overt DIC. Blood, 2013, 122, 3577-3577.	0.6	0
389	Increased Levels Of Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin In End Stage Renal Disease. A Complex Interplay. Blood, 2013, 122, 4742-4742.	0.6	0
390	Thrombotic Biomarker Profiling Of Plasma Samples From Patients Undergoing Bypass Surgery Using Protein Chip Array. Blood, 2013, 122, 3579-3579.	0.6	0
391	Dysregulation Of Thrombotic and Hemostatic Factors In End Stage Renal Disease. Blood, 2013, 122, 4793-4793.	0.6	0
392	Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates. Blood, 2013, 122, 4810-4810.	0.6	0
393	Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation. Blood, 2013, 122, 4770-4770.	0.6	0
394	Usefulness of Dilute Russell's Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants. Blood, 2014, 124, 1537-1537.	0.6	0
395	Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Sameness of Enoxaparin Copies. Blood, 2014, 124, 5092-5092.	0.6	0
396	Recombinant Factor VIIa (rFVIIa) Mediated Activation of Prothrombin Complex Concentrates (PCCs). Studies on the Comparison of Novoseven with a Biosimilar Product. Blood, 2014, 124, 5108-5108.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Augmentation of the Anticoagulant Effects of Heparin By a Tri-Block Polymer MST-188. Blood, 2014, 124, 5080-5080.	0.6	0
398	Increased Biomarkers of Metabolic Syndrome in Total Joint Arthroplasty Patients. FASEB Journal, 2015, 29, 766.8.	0.2	0
399	Dilute Russell's Viper Venom Clotting Time (DRVVT) is Useful for the Routine Monitoring of Newer Non-Vitamin K Anticoagulants. FASEB Journal, 2015, 29, 609.9.	0.2	0
400	Comparative Studies on the Molecular and Functional Profile of Sheep Mucosal Derived Enoxaparin. FASEB Journal, 2015, 29, 927.7.	0.2	0
401	Thrombomodulin Inhibits Tissue factor Mediated Thrombin Generation in blood and Prothrombin Complex Concentrates. FASEB Journal, 2015, 29, 609.11.	0.2	0
402	Bovine and Porcine Mucosal Heparins Exhibit Similar Biologic Profiles. FASEB Journal, 2015, 29, 610.4.	0.2	0
403	Effect of Recombinant Lubricin on Coagulation Parameters in Human Blood. FASEB Journal, 2015, 29, 609.8.	0.2	0
404	Expression of osteopontin and markers of inflammation in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2015, 33, e15122-e15122.	0.8	0
405	Metabolic syndrome marker profile in patients with hepatocellular carcinoma HCC.. Journal of Clinical Oncology, 2015, 33, e22255-e22255.	0.8	0
406	A Generic Version of Recombinant FVIIa Is Similar to the Branded Product (NovoSeven). Blood, 2015, 126, 4746-4746.	0.6	0
407	Role of Platelet Activation in the Pathogenesis of Heart Failure in End-Stage Renal Disease Patients. Blood, 2015, 126, 4636-4636.	0.6	0
408	Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin in End Stage Renal Disease. Blood, 2015, 126, 2312-2312.	0.6	0
409	Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188) As Studied in Agonist Induced Platelet Aggregation Systems. Blood, 2015, 126, 1037-1037.	0.6	0
410	The Potential Role of Ferritin in Relation to Inflammatory and Metabolic Syndrome Biomarkers in Patients Undergoing Total Joint Arthroplasty of the Hip or Knee. Blood, 2015, 126, 4560-4560.	0.6	0
411	Recombinant Thrombomodulin Inhibits Tissue Factor Mediated Thrombin Generation in Blood Plasma and Is Modulated By Prothrombin Complex Concentrates. Blood, 2015, 126, 2303-2303.	0.6	0
412	Cellular and Functional Characterization of Microparticles in Sepsis-Associated Coagulopathy. Blood, 2015, 126, 2297-2297.	0.6	0
413	Baseline Thrombin Generation Markers and Functional Antithrombin Levels in Sepsis Associated Coagulopathies Are Predictive of the Severity of Pathogenesis. Blood, 2015, 126, 4693-4693.	0.6	0
414	Persistent Prothrombotic State in Atrial Fibrillation Despite Use of Novel Oral Anti-Coagulants. Blood, 2016, 128, 3832-3832.	0.6	0

#	ARTICLE	IF	CITATIONS
415	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation. <i>Blood</i> , 2016, 128, 3797-3797.	0.6	0
416	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. <i>Blood</i> , 2016, 128, 3836-3836.	0.6	0
417	Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications. <i>Blood</i> , 2016, 128, 4974-4974.	0.6	0
418	Dabigatran Neutralizing Antibody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications. <i>Blood</i> , 2016, 128, 2622-2622.	0.6	0
419	Platelet Activation in End-Stage Renal Disease Is Mediated By Extracellular Nucleosomes That Originate from White Blood Cells. <i>Blood</i> , 2016, 128, 4909-4909.	0.6	0
420	Increased Extracellular Nucleosome Levels and Microparticles in Atrial Fibrillation Patients Compared to the Age-Matched Normal Population. <i>Blood</i> , 2016, 128, 4912-4912.	0.6	0
421	Relative Neutralization of Heparin from Different Origins by Protamine, Polybrene, Platelet Factor 4, and synthetic heparin antagonist PMX. <i>FASEB Journal</i> , 2018, 32, 570.8.	0.2	0
422	Heparins Derived from Ovine (Sheep) Mucosa are Interchangeable to their Porcine (Pig) Counterparts. <i>FASEB Journal</i> , 2018, 32, 701.5.	0.2	0
423	Differential Neutralization of Unfractionated Heparin, Enoxaparin and Fondaparinux by Andexanet Alpha. <i>FASEB Journal</i> , 2019, 33, 819.12.	0.2	0
424	A Generic Recombinant Factor VIIa is Comparable to the Branded Novoseven in In Vitro and Pharmacokinetic Studies in Primates. <i>FASEB Journal</i> , 2019, 33, 515.4.	0.2	0
425	A Factor Xa Inhibitor Antidote (andexanet alfa) is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate. <i>FASEB Journal</i> , 2019, 33, 1b37.	0.2	0
426	Coagulation and Circulating Heparin Profile in Patients with End-Stage Renal Disease Undergoing Maintenance Hemodialysis. <i>FASEB Journal</i> , 2019, 33, 1b406.	0.2	0
427	Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin. <i>FASEB Journal</i> , 2019, 33, 515.12.	0.2	0
428	Comparative Studies on the Oral Anticoagulant Activities of Orally Active Anti-Xa and Anti-IIa Agents in Whole Blood and Plasma and their Neutralization by FEIBA. <i>FASEB Journal</i> , 2019, 33, 515.2.	0.2	0
429	A Comparison of GMP Manufactured Ovine Mucosal Enoxaparin and Branded Porcine Enoxaparin. <i>FASEB Journal</i> , 2019, 33, 515.11.	0.2	0
430	Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis. <i>FASEB Journal</i> , 2019, 33, 515.1.	0.2	0
431	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. <i>FASEB Journal</i> , 2019, 33, 250.11.	0.2	0
432	Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA. <i>FASEB Journal</i> , 2019, 33, 819.13.	0.2	0

#	ARTICLE	IF	CITATIONS
433	Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery. <i>FASEB Journal</i> , 2019, 33, 819.8.	0.2	0
434	Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Risk of Thromboembolism in Patients with Lymphoma. <i>Blood</i> , 2019, 134, 3649-3649.	0.6	0
435	Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism. <i>Blood</i> , 2019, 134, 2103-2103.	0.6	0
436	Prothrombinase Induced Clotting Time Is More Sensitive than aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma. <i>Blood</i> , 2019, 134, 3374-3374.	0.6	0
437	Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients. <i>Blood</i> , 2019, 134, 2408-2408.	0.6	0
438	Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF- α . Interrelationship between Thrombogenesis and Inflammation. <i>Blood</i> , 2019, 134, 5239-5239.	0.6	0
439	Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis. <i>Blood</i> , 2019, 134, 1155-1155.	0.6	0
440	Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
441	Profiling of Inflammatory Biomarkers and Coagulation Factors in End-Stage Renal Disease. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
442	Altered Coagulation Parameters and D-Dimer Measurements in Sepsis are useful in Scoring the Risk Stratification. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
443	Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti-Xa measurements. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
444	The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110503.	0.7	0
445	Decreased Thrombin Generation Potential in Lymphoma Patients is associated with Increased D-dimer, CRP, vWF and TNF- α . Interrelationship between Thrombogenesis and Inflammation. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
446	Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
447	Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory Processes. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
448	Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Antiheparin Platelet Factor 4 Antibodies as Studied in Platelet Aggregation Assays. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
449	Heparinox, a generic version of low molecular weight heparin enoxaparin, is bioequivalent to the branded version. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
450	Fibrinolytic Dysregulation Contributes to the Hypercoagulable State in Pulmonary Embolism Patients. <i>Blood</i> , 2021, 138, 3177-3177.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. Blood, 2021, 138, 3207-3207.	0.6	0
452	Assay Dependent Reversal of the Oral and Parenteral Anti-Xa Agents By Andexanet Alfa. Blood, 2020, 136, 39-40.	0.6	0
453	Malignant Clonal Cell Proliferation in Multiple Myeloma and the Hypercoagulable State. Blood, 2020, 136, 23-24.	0.6	0
454	Validation of the Bioequivalence of USP Potency Adjusted Porcine, Ovine, and Bovine Heparins. Blood, 2020, 136, 6-6.	0.6	0
455	Isolation and Partial Characterization of A Novel Circulating Antithrombin. Thrombosis and Haemostasis, 1979, , .	1.8	0
456	Safety and efficacy of currently used COVID-19 vaccines: Results of a pilot survey. FASEB Journal, 2022, 36, .	0.2	0
457	Molecular and cellular pathogenesis of endothelial lining in atrial fibrillation. FASEB Journal, 2022, 36, .	0.2	0
458	Thrombo-inflammatory Biomarkers in Patients with End-Stage Renal Disease. FASEB Journal, 2022, 36, .	0.2	0
459	Collagen Remodeling Proteins, Inflammatory Biomarkers and FABP Regulation in Understanding the Pathogenesis of Atrial Fibrillation. FASEB Journal, 2022, 36, .	0.2	0
460	Bioequivalence of Potency Adjusted Approved Heparin Solutions Compared to a Newly Developed Heparin Solution. FASEB Journal, 2022, 36, .	0.2	0
461	Oxidative Stress Biomarkers in Patients with End Stage Renal Disease. FASEB Journal, 2022, 36, .	0.2	0
462	Quantitative TFPI Antigen Release and Functionality After Intravenous Administration of Heparins Sourced From Various Species in Non-human Primates. FASEB Journal, 2022, 36, .	0.2	0
463	USP Potency Adjusted Bovine Mucosal Heparins are Comparable to Porcine Mucosal Heparin and May be Interchangeable for Anticoagulation. FASEB Journal, 2022, 36, .	0.2	0